Eventide Asset Management LLC purchased a new position in shares of Myovant Sciences Ltd (NASDAQ:MYOV) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 295,000 shares of the company’s stock, valued at approximately $3,463,000. Eventide Asset Management LLC owned approximately 0.49% of Myovant Sciences at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the stock. Deerfield Management Co. purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $18,619,000. RA Capital Management LLC raised its stake in Myovant Sciences by 56.6% in the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after buying an additional 848,422 shares in the last quarter. Norges Bank purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $9,763,000. Perceptive Advisors LLC purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $2,815,000. Finally, BB Biotech AG raised its stake in Myovant Sciences by 3.4% in the first quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock worth $38,775,000 after buying an additional 110,000 shares in the last quarter.
Myovant Sciences Ltd (NASDAQ MYOV) traded down 3.43% during midday trading on Tuesday, reaching $11.26. 82,021 shares of the company were exchanged. Myovant Sciences Ltd has a 52 week low of $10.25 and a 52 week high of $15.50. The company has a 50-day moving average of $12.82 and a 200 day moving average of $11.83. The firm’s market capitalization is $678.75 million.
Separately, Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.20.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.